S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

$1.92
-0.24 (-11.09%)
(As of 04/19/2024 ET)
Today's Range
$1.88
$2.17
50-Day Range
$2.15
$3.33
52-Week Range
$1.11
$3.53
Volume
1.17 million shs
Average Volume
418,434 shs
Market Capitalization
$124.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

GlycoMimetics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
419.5% Upside
$10.00 Price Target
Short Interest
Bearish
2.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.49mentions of GlycoMimetics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.54) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.05 out of 5 stars

Medical Sector

163rd out of 911 stocks

Biotechnology Industry

4th out of 33 stocks

GLYC stock logo

About GlycoMimetics Stock (NASDAQ:GLYC)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Stock Price History

GLYC Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
GlycoMimetics Inc
Q4 2023 GlycoMimetics Inc Earnings Call
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
GlycoMimetics: Q4 Earnings Snapshot
GLYC Apr 2024 2.500 call
GLYC Apr 2024 2.500 put
GlycoMimetics Inc hosts conference call for investors
GLYC Apr 2024 5.000 call
Palatin Technologies Inc.
GlycoMimetics Inc GLYC
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2024
Today
4/19/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:GLYC
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+419.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,900,000.00
Pretax Margin
-368,990.00%

Debt

Sales & Book Value

Annual Sales
$10,000.00
Price / Sales
12,406.63
Book Value
$0.60 per share

Miscellaneous

Free Float
58,843,000
Market Cap
$124.07 million
Optionable
Optionable
Beta
2.18
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Harout Semerjian (Age 54)
    CEO, President & Director
    Comp: $1.13M
  • Ms. Rachel K. King (Age 65)
    Co-Founder & Director
    Comp: $40k
  • Mr. Brian M. Hahn (Age 50)
    Senior VP & CFO
    Comp: $822.12k
  • Dr. Edwin Rock M.D. (Age 63)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $677.4k
  • Ms. Stephanie R. Irish CPA (Age 53)
    Vice President of Accounting
  • Mr. Christian B. Dinneen-Long
    General Counsel & Company Secretary
  • Mr. Bruce Johnson (Age 56)
    Senior VP & Chief Commercial Officer
  • Mr. Chinmaya Rath (Age 47)
    Senior VP & Chief Business Officer
  • Mr. Shantha Tyavanagimatt Ph.D.
    Senior Vice President of Technical Operations

GLYC Stock Analysis - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for GlycoMimetics' stock. Their GLYC share price targets range from $8.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 419.5% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2024?

GlycoMimetics' stock was trading at $2.36 on January 1st, 2024. Since then, GLYC stock has decreased by 18.4% and is now trading at $1.9250.
View the best growth stocks for 2024 here
.

Are investors shorting GlycoMimetics?

GlycoMimetics saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,590,000 shares, an increase of 6.7% from the March 15th total of 1,490,000 shares. Based on an average daily trading volume, of 367,100 shares, the days-to-cover ratio is presently 4.3 days.
View GlycoMimetics' Short Interest
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) released its earnings results on Wednesday, March, 27th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. The biotechnology company earned $0.01 million during the quarter.

What other stocks do shareholders of GlycoMimetics own?
How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLYC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners